Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 6/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | METAP1 | P53582 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.37 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125119 | 0.80 | CBFB (0.49) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL19228825 | 0.80 | CBFB (0.41) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL32680229 | 0.78 | CBFB (0.47) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL124418 | 0.78 | CBFB (0.54) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL13064018 | 0.77 | CBFB (0.56) | CBFBALDH1A1PDE10AITKRUNX1 | |
| SCHEMBL19228817 | 0.76 | RUNX1 (0.57) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL19228812 | 0.75 | RUNX1 (0.56) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL19228810 | 0.74 | RUNX1 (0.65) | ALDH1A1RUNX1POLB | |
| SCHEMBL19228826 | 0.73 | ALOX5 (0.46) | CBFBMETAP2METAP1NPC1RAB9A | |
| SCHEMBL179108 | 0.73 | CBFB (0.60) | CBFBNPC1RAB9APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | CBFB 2/4885METAP2 4282/4885METAP1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.